Treatment of recurrent lung cancer using alpha radiation emitters
A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Recurrent Lung Cancer
This study is testing a new way to treat recurrent lung cancer by using a device that puts tiny seeds delivering alpha radiation directly into tumors to see if it’s safe and effective.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Alpha Tau Medical LTD. Industry-sponsored |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Jerusalem) |
| Trial ID | NCT05632913 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility and safety of a novel treatment for recurrent lung cancer using a device that delivers diffusing alpha radiation directly into tumors. It involves a single center, open-label approach where eligible patients will undergo the insertion of DaRT seeds into their tumors. Following the procedure, participants will be monitored for a short-term period of 4-8 weeks and a long-term follow-up of 3 months to assess treatment outcomes. A total of 10 subjects will be enrolled in this prospective study.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed recurrent mediastinal tumors that can be treated with alpha radiation.
Not a fit: Patients with lesions larger than 3 cm or those with a life expectancy of less than 6 months may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with recurrent lung cancer who have limited treatment alternatives.
How similar studies have performed: While this approach is novel, similar studies using localized radiation therapies have shown promise in treating various cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically and/or cytologically proven recurrent mediastinal tumors * Target lesion is technically amenable for at least 50% coverage by the Alpha DaRT seeds as determined by the treating physician * Up to two treatable lesions * Interstitial radiation indication validated by a multidisciplinary team. * Measurable lesion per RECIST (version 1.1) criteria * Lesion size ≤ 3 cm in the longest diameter * Age ≥18 years old * ECOG Performance Status Scale ≤ 3 * Life expectancy is more than 6 months * WBC ≥ 3500/µl, granulocyte ≥ 1500/µl * Platelet count ≥60,000/µl * Calculated or measured creatinine clearance ≥ 60cc/min. Calculated, or measured creatinine clearance can be≥ 40cc/min given stability of creatinine levels over the past three weeks (at least 1 test per week). * AST and ALT ≤ 2.5 X ULN * INR \< 1.4 for patients not on Warfarin * Subjects are willing and able to sign an informed consent form * Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy. Exclusion Criteria: * Concomitant chemotherapy or immunotherapy * Brain metastases Connective tissue disease (scleroderma, lupus) * Known hypersensitivity to any of the components of the treatment. * Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids. * Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months. * Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints. * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. * Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT. * Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. * Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT. * High probability of protocol non-compliance (in opinion of investigator). * Breastfeeding women or women of childbearing potential unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT.
Where this trial is running
Jerusalem
- Hadassah University Hospital — Jerusalem, Israel (Recruiting)
Study contacts
- Principal investigator: Aron Popovtzer, MD — Hadassah Medical Organization
- Study coordinator: Liron Dimnik
- Email: LironD@alphatau.com
- Phone: +972237377000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.